All In MedTech

FDA Clearance Tracker · P190032-S011

FoundationOne Liquid CDx (F1LCDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 11, 2023

Approved

Time to decision

230 days

Received Feb 23, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P190032-S011
Device name
FoundationOne Liquid CDx (F1LCDx)
Applicant location
Boston, MA
Received
Feb 23, 2023
Decided
Oct 11, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval to include a companion diagnostic indication for the detection of BRAF V600E in patients with non-small cell lung cancer who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib).

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.